MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Infinity Pharmaceuticals Company Profile (NASDAQ:INFI)

Consensus Ratings for Infinity Pharmaceuticals (NASDAQ:INFI) (?)
Ratings Breakdown: 9 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $6.75 (389.13% upside)

Analysts' Ratings History for Infinity Pharmaceuticals (NASDAQ:INFI)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016FBR & Co.Reiterated RatingMarket Perform$2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016WedbushReiterated RatingNeutral$1.25View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Jefferies GroupDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016William BlairDowngradeOutperform -> Market Perform$20.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Wells FargoDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Morgan StanleyDowngradeOverweight -> Equal WeightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016RBC CapitalDowngradeOutperform -> Sector Perform$12.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2015Stifel NicolausReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2015NomuraReiterated RatingNeutral -> Buy$17.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Deutsche BankInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2014Credit SuisseUpgradeNeutral -> Outperform$20.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/3/2014Roth CapitalReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Infinity Pharmaceuticals (NASDAQ:INFI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/4/2016Q116($0.82)($0.82)$8.80 million$9.26 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q415($0.72)($0.80)$18.26 million$9.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.63)$0.84$24.85 million$90.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($1.00)($0.78)$5.83 million$4.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($1.68)($1.91)$5.79 million$4.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q414($0.98)($0.83)$5.61 million$4.36 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314$0.30$2.03$141.40 million$160.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q114($0.84)($0.78)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q1($0.83)($0.87)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2014Q413($0.87)($0.68)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013($0.75)($0.71)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.62)($0.68)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2012Q312($0.57)$0.52$13.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.91)($0.79)($0.85)
Q2 20164($1.02)($0.83)($0.92)
Q3 20164($0.89)($0.76)($0.83)
Q4 20164($1.04)$3.15$1.07
Q1 20171($0.14)($0.14)($0.14)
Q2 20171($0.14)($0.14)($0.14)
Q3 20171($0.14)($0.14)($0.14)
Q4 20171($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)
Dividend History for Infinity Pharmaceuticals (NASDAQ:INFI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Infinity Pharmaceuticals (NASDAQ:INFI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/25/2015Adelene Q PerkinsCEOSell5,000$10.93$54,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Vito J PalombellaInsiderSell4,737$10.97$51,964.89View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2015Adelene Q PerkinsCEOSell10,000$12.81$128,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2015Adelene Q PerkinsCEOSell10,000$12.18$121,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Adelene Q PerkinsCEOSell20,000$16.00$320,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2015Adelene Q PerkinsCEOSell20,000$14.83$296,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Vito J PalombellaInsiderSell4,737$16.32$77,307.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014Vito J PalombellaInsiderSell4,736$15.00$71,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014Anthony B EvninDirectorSell112,451$13.56$1,524,835.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2014Vito J PalombellaInsiderSell9,472$15.39$145,774.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2013Anthony B EvninDirectorSell163,864$14.82$2,428,464.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Adelene PerkinsCEOSell45,000$20.72$932,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2013Vito J PalombellaInsiderSell23,150$18.53$428,969.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2012Christopher M LindblomInsiderSell13,885$25.73$357,261.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/7/2012Co BeaconMajor ShareholderBuy5,416,565$14.50$78,540,192.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Infinity Pharmaceuticals (NASDAQ:INFI)
DateHeadline
06/29/16 10:08 AMInfinity Regains Duvelisib Rights, Announces Restructuring -
06/29/16 07:29 AMInvestor News: Infinity Pharmaceuticals Inc. (NASDAQ:INFI) under Investigation - GroundReport
06/29/16 07:29 AMBRIEF-Infinity Pharmaceuticals sees workforce restructuring completed by year-end - Reuters
06/29/16 07:29 AMInfinity Pharma cuts 100 jobs after AbbVie deal is terminated - The Boston Globe
06/29/16 07:21 AMCall announcement Infinis plc annual results for the year ending 31 March 2016 £350m 7% Senior Notes due 2019 - [at noodls] - Fax transmission 29 June 2016 Annual Results Announcement £350 million 7% Senior Notes due 2019 Infinis plc (the "Issuer"), an indirectly wholly-owned subsidiary of Infinis Energy Limited (formerly ...
06/28/16 04:35 PMAbbVie Ends Collaboration with Infinity
06/28/16 04:35 PMInfinity Pharma cuts 100 jobs after AbbVie deal is terminated
06/28/16 04:35 PMAbbVie (ABBV) Exercises Right to End Duvelisib Collaboration with Infinity Pharma (INFI)
06/28/16 09:34 AMInfinity Pharmaceuticals : Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration
06/28/16 07:22 AMINFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Costs Associated w -
06/28/16 06:11 AMInfinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration - [at noodls] - CAMBRIDGE, Mass., June 28, 2016 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that AbbVie Inc. has exercised its right to end its collaboration with Infinity to develop ...
06/27/16 04:38 PMShares in Oversold Area: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Press Telegraph
06/27/16 04:38 PMNoteworthy Stocks: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) , Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) - Street Updates
06/26/16 08:31 AM7 Stocks Under $10 to Trade for Big Post-Brexit Gains -
06/25/16 04:20 PMEarnings Surprise in Focus: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Investor Newswire
06/23/16 07:33 AMWilliam Blair Downgrades Infinity Pharmaceuticals to Market Perform - TheFounders Daily
06/23/16 07:33 AMInfinity Pharmaceuticals Inc. (INFI) Drops 5.04% on June 21 - Equities.com
06/23/16 07:33 AMInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Stock Momentum Hits EXTREME Weakness - CML News
06/22/16 04:45 PMInvestor Investigation over Potential Wrongdoing Infinity Pharmaceuticals Inc. (NASDAQ:INFI)
06/22/16 03:44 PMINFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/22/16 09:18 AMInfinity Pharmaceuticals (NASDAQ:INFI) Analyst Rating Consensus - Trade Calls
06/22/16 09:18 AMInfinity Pharmaceuticals Inc. (INFI) Drops 8.55% on June 20 - Equities.com
06/21/16 04:21 PMInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Current Analyst Ratings - Fiscal Standard
06/20/16 04:28 PMAttentive Stocks in Active Notes: Ceres (NASDAQ:CERE), Infinity Pharmaceuticals (NASDAQ:INFI), Commercial Metals ... - Seneca Globe
06/20/16 01:37 PMETF’s with exposure to Infinity Pharmaceuticals, Inc. : June 20, 2016 -
06/17/16 04:31 PMInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Insiders Look Pessimistic About Prospects
06/16/16 04:41 PMInfinity Pharmaceuticals Inc. (INFI) Rating Lowered to Hold at Jefferies Group
06/16/16 08:54 AMInfinity Pharmaceuticals Inc. (NASDAQ:INFI) Slashes Value By 70% Following Less-Than-Stellar Clinical Results
06/16/16 08:54 AMInfinity Pharma shares dumped after Phase II trial misses expectations
06/16/16 08:54 AMInfinity Pharmaceuticals’ (INFI) Weak Trial Data Forces Layoffs
06/15/16 04:41 PMAnalyst Downgrades: Bed Bath & Beyond Inc., Infinity Pharmaceuticals Inc., and GoPro Inc - Schaeffers Research (blog)
06/15/16 04:41 PMInfinity Pharmaceuticals Inc. (INFI) Jumps 10.29% on June 15 - Equities.com
06/15/16 02:30 PMInfinity Pharmaceuticals Faces Downgrades as Drug Results Disappoint -
06/15/16 01:32 PMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Infinity Pharmaceuticals Inc. (INFI) - [PR Newswire] - NEW YORK, June 15, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Infinity Pharmaceuticals ...
06/15/16 12:30 PMInfinity Pharmaceuticals Cannot Cure Downgrades After Drug Study -
06/15/16 09:15 AMHC Stocks Growth: Biostar Pharmaceuticals Inc (NASDAQ:BSPM), Infinity Pharmaceuticals Inc. (NASDAQ:INFI) - share market updates (press release)
06/15/16 09:15 AMEarnings Trend of the Stocks: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), JPMorgan Chase & Co. (NYSE:JPM) - Beacon Chronicle
06/15/16 09:15 AMInfinity Pharmaceuticals Inc. (INFI) Drops 8.32% on June 13 - Equities.com
06/15/16 05:21 AMInfinity Pharmaceutical downgraded by RBC Capital Mkts -
06/14/16 04:29 PMInfinity Pharmaceuticals stock plunges toward record low after drug study disappoints - MarketWatch
06/14/16 04:29 PMWhy Infinity Pharmaceuticals Inc. Is Being Obliterated Today - Motley Fool
06/14/16 03:38 PMInfinity Pharmaceuticals (INFI) Stock Tanks on Lymphoma Drug Letdown - <p><a rel="nofollow" href="http://investorplace.com">InvestorPlace</a><a rel="nofollow" href="http://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>Infinity Pharmaceuticals stock plummeted as the company announced a restructuring following disappointing results in a lymphoma drug trial.</p> <p>The post <a rel="nofollow" href="http://investorplace.com/2016/06/infinity-pharmaceuticals-infi-stock/">Infinity Pharmaceuticals (INFI) Stock Tanks on Lymphoma Drug Letdown</a> appeared first on <a rel="nofollow" href="http://investorplace.com">InvestorPlace</a>.</p>
06/14/16 12:39 PMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Infinity Pharmaceuticals, Inc. - [Business Wire] - Levi & Korsinsky announces it has commenced an investigation of Infinity Pharmaceuticals, Inc. concerning possible violations of federal securities laws.
06/14/16 12:13 PMMid-Day Market Update: Yingli Green Energy Surges Following Q1 Earnings; Infinity Pharmaceuticals Shares Tumble -   Midway through trading Tuesday, the Dow traded down 0.52 percent to 17,640.81 while the NASDAQ declined 0.48 percent to 4,825.04. The S&P also fell, dropping 0.45 percent to 2,069.67. Leading and Lagging Sectors <b>On Tuesday, non-cyclical consumer goods & services shares slipped by just 0.1 percent. In trading on Tuesday, basic materials shares declined by 1.7 percent. Meanwhile, top losers in the sector included Endeavour Silver Corp (NYSE: EXK), down 7 percent, and Teck Resources Ltd (USA) (NYSE: TCK), down 7 percent. Top Headline Isle of Capri Casinos (NASDAQ: ISLE) reported better-than-expected earnings for its fourth quarter on Tuesday. The company posted adjusted earnings of $0.62 per share on revenue of $264.9 million. However, analysts were expecting earnings of 0.54 per share on revenue of $266.8 million. Equities Trading UP Leading Brands, Inc (USA) (NASDAQ: LBIX) shares shot up 53 percent to $2.29 following Q1 results. Leading Brands reported Q1 earnings of $0.10 per share on revenue of $3.033 million. Shares of Vonage Holdings Corp. (NYSE: VG) got a ...Full story available on Benzinga.com
06/14/16 11:48 AMWhy Infinity Pharmaceuticals Inc. Is Being Obliterated Today - Disappointing results from a clinical trial cause traders to head for the exits.
06/14/16 10:25 AMWhy Infinity Pharmaceuticals Crashed -
06/14/16 09:28 AMVeracyte, Inc. (NASDAQ:VCYT) plummeted -5.69%: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), AVG Technologies ... - KC Register
06/14/16 09:28 AMBRIEF-Infinity Pharmaceuticals expects to incur total restructuring costs of about $6 to $8 mln - Reuters
06/14/16 09:28 AMBRIEF-Infinity Pharmaceuticals Inc reports topline results from DYNAMO(tm) - Reuters
06/14/16 09:28 AMBuzz Stocks: Alibaba Group Holding Ltd, Infinity Pharmaceuticals Inc., and Valeant Pharmaceuticals Intl Inc - Schaeffers Research (blog)
About Infinity Pharmaceuticals

Infinity Pharmaceuticals logoInfinity Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies. In addition to duvelisib, the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies), a worldwide investigation of duvelisib in blood cancers.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: INFI
  • CUSIP: 45665G30
Key Metrics:
  • Previous Close: $1.38
  • 50 Day Moving Average: $3.91
  • 200 Day Moving Average: $5.67
  • P/E Ratio: N/A
  • P/E Growth: -0.01
  • Market Cap: $68.24M
  • Current Quarter EPS Consensus Estimate: $-2.24 EPS
Additional Links:
Infinity Pharmaceuticals (NASDAQ:INFI) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha